SXI Life Sciences
7.097,13
PKT
-2,19
PKT
-0,03
%
Werbung
Analysen zu SXI Life Sciences-Werten
Datum | Rating | Analyst | |
---|---|---|---|
14.04.05 | Novartis Reduce | UBS | |
14.04.05 | Novartis Reduce | UBS | |
14.04.05 | Roche Halten | Helaba Trust | |
15.04.05 | Novartis Underperform | Credit Suisse First Boston | |
15.04.05 | Roche Buy | SES Research | |
13.04.05 | Lonza Reduce | Sarasin Research | |
13.04.05 | Novartis Neutral | Sarasin Research | |
11.04.05 | Lonza Overweight | JP Morgan | |
08.04.05 | Novartis Accumulate | Helvea | |
07.04.05 | Lonza Reduce | Sarasin Research | |
06.04.05 | Roche Buy | Helvea | |
29.03.05 | Siegfried Sector Perform | Vontobel | |
29.03.05 | Roche Buy | Sarasin Research | |
24.03.05 | Roche Sector Outperform | Vontobel | |
23.03.05 | Kuros (Kuros Biosciences) Sector Outperform | Vontobel | |
22.03.05 | Siegfried Neutral | Helvea | |
22.03.05 | Roche Buy | Sarasin Research | |
22.03.05 | Novartis Accumulate | Helvea | |
21.03.05 | Novartis Neutral | Sarasin Research | |
21.03.05 | Novartis Kaufen | Helaba Trust | |
21.03.05 | Novartis Neutral | Sarasin Research | |
21.03.05 | Tecan (N) Sector Perform | Vontobel | |
17.03.05 | Roche Buy | Helvea | |
17.03.05 | Novartis Outperform | Goldman Sachs | |
17.03.05 | Tecan (N) Reduce | Helvea | |
17.03.05 | Roche In-Line | Goldman Sachs | |
11.03.05 | Novartis Buy | Helvea | |
11.03.05 | Novartis Neutral | Sarasin Research | |
10.03.05 | Novartis Neutral | Sarasin Research | |
10.03.05 | Roche Buy | Sarasin Research | |
09.03.05 | Novartis Buy | Merrill Lynch | |
07.03.05 | Roche Neutral | Helvea | |
08.03.05 | Novartis Neutral | Sarasin Research | |
08.03.05 | Roche Neutral | Helvea | |
01.03.05 | Roche Buy | Sarasin Research | |
24.02.05 | Novartis Overweight | Lehman Brothers | |
22.02.05 | Novartis Buy | Helvea | |
23.02.05 | Novartis Outperform | Goldman Sachs | |
21.02.05 | Straumann Outperform | Goldman Sachs | |
22.02.05 | Novartis Kaufen | Helaba Trust |